Partial
Mostly Aligned
Patient Risk:
Low
Summary
Evaluation shows correct alignment on indication and mechanism, but substantial safety gaps and unsupported analgesic-interaction claims reduce overall alignment.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication used to lower cholesterol levels.
Indication; Mechanism of Action
Lipitor works by inhibiting the enzyme HMG-CoA reductase, which is responsible for producing cholesterol in the liver.
12.1 Mechanism of Action
Unsupported Statements
Some patients have reported that taking Lipitor increases the potency of their painkillers.
Label does not discuss interactions with painkillers or analgesic potency; only mentions interactions with certain drug classes (e.g., strong CYP3A4 inhibitors).
A study published in the Journal of Clinical Pharmacology found that atorvastatin increased the potency of morphine in rats.
No study data on morphine potency described in label.
The study suggested that the increased potency was due to the inhibition of the enzyme CYP3A4, which is responsible for producing morphine.
Label does not discuss morphine metabolism or CYP3A4-mediated analgesic potency changes.
A study published in the European Journal of Pain found that atorvastatin increased the analgesic effect of tramadol in patients with chronic pain.
No such analgesic interaction described in label.
The study suggested that the increased analgesic effect was due to the inhibition of the enzyme CYP2D6, which is responsible for metabolizing tramadol.
Label does not discuss tramadol metabolism or CYP2D6 interactions.
DrugPatentWatch.com states that atorvastatin (Lipitor) can interact with various painkillers, including morphine, tramadol, and oxycodone.
Label does not reference interactions with these analgesics; only generic drug interaction language is present.
These interactions can lead to increased potency or toxicity of the painkiller.
Label does not describe analgesic potency or toxicity changes related to painkillers.
There is some evidence to suggest Lipitor can increase the potency of painkillers; more research is needed to fully understand the underlying mechanisms.
No such evidence or call for more research on analgesic potency interactions is described in the label.
Lipitor can interact with painkillers, including morphine, tramadol, and oxycodone.
The label does not mention interactions with these specific painkillers.
Patients should always consult with their healthcare provider before taking any new medications, especially if they are already taking painkillers.
Label includes counseling about substances not to take concomitantly and informing healthcare professionals when starting a new medication.
While Lipitor can increase the potency of painkillers, it is generally considered safe to take with painkillers.
Label does not state general safety with painkillers; warns about interactions that increase risk of myopathy.
Contradictions
Important Omissions
Missing explicit contraindications for atorvastatin (e.g., active hepatic disease, hypersensitivity).
Importance:
High
Missing pregnancy risk information; statins are contraindicated in pregnancy and lactation.
Importance:
High
Missing pediatric safety information; labeling commonly includes pediatric use or restrictions.
Importance:
High
Missing dosing safety details (starting dose, dosing range, hepatic impairment adjustments, monitoring).
Importance:
High
No explicit note about the absence of a boxed warning; label typically contains warnings about myopathy and liver injury, not a boxed warning.
Importance:
Medium
Analgesic interaction claims attributed to external sources are not supported by the label; need alignment with Drug Interactions section.
Importance:
High
Omission of guidance on grapefruit juice interactions (if applicable to the label).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
No new safety concerns identified beyond known labeling; unsupported analgesic interaction claims reduce alignment.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Missing critical safety topics (contraindications, pregnancy, pediatric use, dosing safety) and several unsupported analgesic-interaction claims.
Suggested Improvement
Verify analgesic-interaction claims against Drug Interactions; explicitly include contraindications, pregnancy and lactation warnings, pediatric use guidance, and dosing/monitoring details; cite label sections by name.